Publications by authors named "M E Bannister"
Hepatocellular carcinoma (HCC) represents a significant clinical burden globally and is predicted to continue to increase in incidence for the foreseeable future. The treatment of HCC is complicated by the fact that, in the majority of cases, it develops on a background of advanced chronic inflammatory liver disease. Chronic inflammation can foster an immunosuppressive microenvironment that promotes tumour progression and metastasis.
View Article and Find Full Text PDFArticle Synopsis
- ADP-ribosylation is a process where ADP-ribose units are transferred from NAD+ to proteins, and its dysregulation is linked to neurodegenerative diseases.
- A study used genetic testing on two siblings suffering from developmental issues, seizures, and muscle weakness, identifying a new variant in the ADPRS gene that contributes to their diagnosis of childhood-onset neurodegeneration with stress-induced ataxia and seizures (CONDSIAS).
- The identified genetic variant affects the protein ARH3, leading to its instability, improper localization, and accumulation of harmful compounds, helping to explain the disease's mechanisms and the importance of ARH3 in maintaining nervous system health.
Modeling immune cell recruitment by liver endothelial cells in vitro is important to better understand the pathology of chronic inflammatory liver diseases and cancers. Here, we present a protocol for the study of monocyte transmigration across activated primary human liver endothelial cells, under physiological flow conditions. We describe primary endothelial cell isolation from human liver tissues and monocyte isolation from human blood.
View Article and Find Full Text PDFPurpose: ADP-ribosylation is a post-translational modification involving the transfer of one or more ADP-ribose units from NAD+ to target proteins. Dysregulation of ADP-ribosylation is implicated in neurodegenerative diseases. Here we report a novel homozygous variant in the gene (c.
View Article and Find Full Text PDFArticle Synopsis
- The Comet Interceptor mission aims to explore a long-period comet or an interstellar object entering our Solar System, with a focus on its surface composition, shape, and the composition of its gas and dust.
- Proposed to the European Space Agency in 2018 and approved in June 2022, it is set to launch in 2029 alongside the Ariel mission, utilizing a low-cost approach that allows it to wait for a suitable target comet.
- The mission will feature a main probe and two sub-probes (B1 from JAXA and B2), providing simultaneous, detailed 3D information about the comet and its interaction with the solar wind, making it unique compared to previous missions.